Your browser doesn't support javascript.
loading
The selective 5-HT1F receptor agonist lasmiditan inhibits trigeminal nociceptive processing: Implications for migraine and cluster headache.
Vila-Pueyo, Marta; Page, Keith; Murdock, Paul R; Loraine, Howard J; Woodrooffe, Amanda J; Johnson, Kirk W; Goadsby, Peter J; Holland, Philip R.
Affiliation
  • Vila-Pueyo M; Headache Group, Wolfson Centre for Age-Related Diseases, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
  • Page K; Cerevance, Cambridge, UK.
  • Murdock PR; Precision for Medicine, Royston, UK.
  • Loraine HJ; Precision for Medicine, Royston, UK.
  • Woodrooffe AJ; Precision for Medicine, Royston, UK.
  • Johnson KW; Neuroscience Discovery, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA.
  • Goadsby PJ; Headache Group, Wolfson Centre for Age-Related Diseases, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
  • Holland PR; Headache Group, Wolfson Centre for Age-Related Diseases, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Br J Pharmacol ; 179(3): 358-370, 2022 Feb.
Article in En | MEDLINE | ID: mdl-34600443
ABSTRACT
BACKGROUND AND

PURPOSE:

Lasmiditan is a novel selective 5-HT1F receptor agonist, recently approved for acute treatment of migraine. 5-HT1F receptors are widely expressed in the CNS and trigeminovascular system. Here, we have explored the therapeutic effects of 5-HT1F receptor activation in preclinical models of migraine and cluster headache. EXPERIMENTAL

APPROACH:

Electrical stimulation of the dura mater or the superior salivatory nucleus in anaesthetised rats evoked trigeminovascular or trigeminal-autonomic reflex activation at the level of the trigeminocervical complex. Additionally, cranial autonomic manifestations in response to trigeminal-autonomic reflex activation were measured, via anterior choroidal blood flow alterations. These responses were then challenged with lasmiditan. We explored the tissue distribution of mRNA for 5-HT1F receptors in human post-mortem tissue and of several 5-HT1 receptor subtypes in specific tissue beds. KEY

RESULTS:

Lasmiditan dose-dependently reduced trigeminovascular activation in a preclinical model of migraine. Lasmiditan also reduced superior salivatory nucleus-evoked activation of the trigeminal-autonomic reflex, but had no effect on cranial autonomic activation. mRNA profiling in human tissue showed expression of the 5-HT1F receptor in several structures relevant for migraine and cluster headache. CONCLUSION AND IMPLICATIONS Our data suggest that lasmiditan acts, at least in part, as an anti-migraine agent by reducing trigeminovascular activation. Furthermore, our results highlight a clear action for lasmiditan in a preclinical model of cluster headache. Given the proven translational efficacy of this model, our data support the potential utility of lasmiditan as a therapeutic option for the acute treatment of cluster headache attacks. LINKED ARTICLES This article is part of a themed issue on Advances in Migraine and Headache Therapy (BJP 75th Anniversary). To view the other articles in this section visit http//onlinelibrary.wiley.com/doi/10.1111/bph.v179.3/issuetoc.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cluster Headache / Migraine Disorders Limits: Animals Language: En Journal: Br J Pharmacol Year: 2022 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cluster Headache / Migraine Disorders Limits: Animals Language: En Journal: Br J Pharmacol Year: 2022 Document type: Article Affiliation country: